Abbreviations used in this paper: GLP-1 glucagon-like peptide-1 GLP-1R GLP-1 receptor T2D type 2 diabetes mellitus GLP-1RA GLP-1R agonists GPCR G-protein coupled receptor cAMP cyclic adenosine monophosphate PKA protein kinase A FDA Food and Drug Administration LPS lipopolysaccharide ALI acute lung injury OVA ovalbumin Th2 CD4+ T-helper type 2 ILC2s group 2 innate lymphoid cells IL-33 interleukin-33 DC dendritic cells FEV 1 forced expiratory volume in one second FVC forced vital capacity Th2-high type 2 inflammation high Th2-low type 2 inflammation low BALF bronchoalveolar lavage fluid TSLP thymic stromal lymphopoietin NO nitric oxide DPP-IV dipeptidyl peptidase IV GATA-3 Glucagon-like peptide-1 receptor Agonist Treatment in Adult, obesity-replated, symptomatic asthma Footnotes Conflicts of interest: KN Cahill has served on scientific advisory boards for GlaxoSmithKline, Regeneron, Genentech, Sanofi, Novartis, and AztraZeneca and served as a consultant for Ribon Therapeutics and Verantos outside the submitted work
TrimRxs Approach to Personalized Weight Loss and Health At TrimRx, we understand that every individuals journey toward health and well-being is unique
Most GLP-1 medications do not significantly affect the blood levels of standard oral contraceptive pills
This was due to our decision to apply L1 regulation in order to obtain the simplest model for the purpose of helping clinicians determine which of their patients with T2D would most likely benefit from adding GLP-1 M as the second-line medication
Genetic testing through a Precision Peptide panel can supplement this assessment by revealing peptide pathway predispositions
